Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection
作者:Qi Li、Ying Chen、Shuaishuai Xing、Qinghong Liao、Baichen Xiong、Yuanyuan Wang、Weixuan Lu、Siyu He、Feng Feng、Wenyuan Liu、Yao Chen、Haopeng Sun
DOI:10.1021/acs.jmedchem.1c00167
日期:2021.5.27
Butyrylcholinesterase (BChE) has been considered as a potential therapeutic target for Alzheimer’s disease (AD) because of its compensation capacity to hydrolyze acetylcholine (ACh) and its close association with Aβ deposit. Here, we identified S06-1011 (hBChE IC50 = 16 nM) and S06-1031 (hBChE IC50 = 25 nM) as highly effective and selective BChE inhibitors, which were proved to be safe and long-acting
丁酰胆碱酯酶(BChE)因其水解乙酰胆碱(ACh)的补偿能力及其与Aβ沉积的密切关系而被认为是阿尔茨海默病(AD)的潜在治疗靶点。在这里,我们确定了S06-1011 ( h BChE IC 50 = 16 nM) 和S06-1031 ( h BChE IC 50 = 25 nM) 为高效、选择性 BChE 抑制剂,并被证明是安全且长效的。候选化合物在东莨菪碱和 Aβ 1-42肽诱导的认知缺陷模型中表现出神经保护作用和改善认知的能力。最佳候选者S06-1011提高了BChE底物ghrelin的水平,可以起到改善精神情绪食欲的作用。 S06-1011处理组的体重增加显着增加。因此,抑制BChE不仅对痴呆具有保护作用,而且对治疗和护理也有很大作用。